Joseph M. Miller

CIK: 0001746372

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (20.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)3 (30.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

LBRX

LB PHARMACEUTICALS INC

Officer

AUPH

Aurinia Pharmaceuticals Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

LBRX
LB PHARMACEUTICALS INC
Oct 9, 2026
Award(A)
Emplopyee Stock Option (Right to Buy)
Direct
200K shares-
AUPH
Aurinia Pharmaceuticals Inc.
Mar 2, 2026
Tax Payment(F)
Direct
37.5K shares at avg. $14.21$533K
AUPH
Aurinia Pharmaceuticals Inc.
Feb 27, 2026
Award(A)
Direct
57.2K shares-
AUPH
Aurinia Pharmaceuticals Inc.
Feb 20, 2026
Tax Payment(F)
Direct
32.4K shares at avg. $14.40$467K
AUPH
Aurinia Pharmaceuticals Inc.
Jan 2, 2026
Tax Payment(F)
Direct
40.2K shares at avg. $15.95$641K
AUPH
Aurinia Pharmaceuticals Inc.
Jan 2, 2026
Award(A)
Direct
49K shares-
AUPH
Aurinia Pharmaceuticals Inc.
Mar 4, 2025
Sale(S)
Direct
56.2K shares at avg. $7.92$445K
AUPH
Aurinia Pharmaceuticals Inc.
Mar 3, 2025
Award(A)
Direct
114.7K shares-
AUPH
Aurinia Pharmaceuticals Inc.
Mar 3, 2025
Sale(S)
Direct
61.9K shares at avg. $8.00$495K
AUPH
Aurinia Pharmaceuticals Inc.
Feb 28, 2025
Award(A)
Direct
81.5K shares-

		Type	Shares	Price		Ownership
Oct 9, 2026	LBRX LB PHARMACEUTICALS INC	Award(A) Emplopyee Stock Option (Right to Buy)	200,000	-	-	Direct
Mar 2, 2026	AUPH Aurinia Pharmaceuticals Inc.	Tax Payment(F)	37,511	$14.21	$533,031	Direct
Feb 27, 2026	AUPH Aurinia Pharmaceuticals Inc.	Award(A)	57,229	-	$0	Direct
Feb 20, 2026	AUPH Aurinia Pharmaceuticals Inc.	Tax Payment(F)	32,424	$14.40	$466,906	Direct
Jan 2, 2026	AUPH Aurinia Pharmaceuticals Inc.	Tax Payment(F)	40,161	$15.95	$640,568	Direct
Jan 2, 2026	AUPH Aurinia Pharmaceuticals Inc.	Award(A)	49,038	-	$0	Direct
Mar 4, 2025	AUPH Aurinia Pharmaceuticals Inc.	Sale(S)	56,154	$7.92	$444,740	Direct
Mar 3, 2025	AUPH Aurinia Pharmaceuticals Inc.	Award(A)	114,711	-	-	Direct
Mar 3, 2025	AUPH Aurinia Pharmaceuticals Inc.	Sale(S)	61,859	$8.00	$494,872	Direct
Feb 28, 2025	AUPH Aurinia Pharmaceuticals Inc.	Award(A)	81,457	-	-	Direct

1-10 of 10 transactions

About Miller Joseph M

Miller Joseph M (SEC CIK 0001746372) files insider reports with the SEC as Chief Financial Officer of LB PHARMACEUTICALS INC (LBRX) and Chief Financial Officer of Aurinia Pharmaceuticals Inc. (AUPH).

Signal8 holds 6 ownership filings by Miller Joseph M (1 Form 3, 5 Form 4), filed between Mar 4, 2025 and Oct 13, 2026. Those filings report 10 transactions, from Feb 28, 2025 to Oct 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Miller Joseph M's filings is in NEW YORK, NY.

Recent filings by Miller Joseph M

Oct 9, 2026: Grant or award of LBRX derivative securities (Form 4, code A).
Mar 2, 2026: Tax withholding of AUPH shares (Form 4, code F).
Feb 27, 2026: Grant or award of AUPH shares (Form 4, code A).
Feb 20, 2026: Tax withholding of AUPH shares (Form 4, code F).
Jan 2, 2026: Tax withholding of AUPH shares (Form 4, code F).

Other insiders filing for LB PHARMACEUTICALS INC (LBRX)

Kozauer Susan Gani, Chief Medical Officer
Deep Track Biotechnology Master Fund, Ltd., 10% Owner
RUFFOLO ROBERT R, Director
Nussbaum Ran, Director
Luse Rebecca, Director
Lenz Robert A., Director

How to read Form 4 transaction codes